Illumina Names Sanjay Chikarmane as Senior Vice President and General Manager of Enterprise Informatics
July 20 2015 - 4:05PM
Business Wire
Illumina Inc. (NASDAQ:ILMN) today announced
that Sanjay Chikarmane has been named Senior Vice President
and General Manager of Illumina’s Enterprise Informatics business.
Chikarmane will lead the development and commercialization of
products and services aimed at turning genomic data into actionable
information for researchers and clinicians. He will report to
Illumina President, Francis deSouza.
“Given the growing data intensive demands of the genomics
market, we felt it critical to bring in a group leader dedicated to
driving our informatics strategy,” said Francis deSouza,
President of Illumina. “Sanjay is an excellent addition to
Illumina’s leadership team and will be instrumental in growing our
enterprise informatics business, defining our software development
processes and service delivery architecture that will be used
across all of Illumina.”
Nick Naclerio who led the acquisition of NextBio and served as
the founding General Manager of the Enterprise Informatics business
unit will return to the full-time role of Senior Vice President of
Corporate Development.
Chikarmane joins Illumina with more than 20 years of experience
in enterprise software at companies including HP, BEA Systems and
most recently, SAP. Through his career, he has held a variety of
leadership roles in enterprise software, including general
management, go-to-market, product management and product
development, during which he has successfully created and scaled
several market leading products. While at SAP, Chikarmane oversaw
several key products including industry solutions for big data
analytics on the HANA platform, cloud business networks, data
management and middleware, including their adoption by top
customers.
Chikarmane holds a Bachelor of Technology degree in Electrical
Engineering from the Indian Institute of Technology (IIT), Bombay,
India and a Master of Science in Computer Engineering from Syracuse
University.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150720005855/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Jennifer Temple,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024